National Medical Products Administration (NMPA)
Is Liraglutide legal in China?
Approved generic versions are sold.
The originator liraglutide entered the Chinese market in 2011 for adults with type 2 diabetes. NMPA approved Tonghua Dongbao's biosimilar liraglutide injection in December 2023 and Zhifei's subsidiary's biosimilar in July 2026, the latter for blood-sugar control and for lowering major heart and circulation events in adults with type 2 diabetes and cardiovascular disease. Zhifei's filing states that, per NMPA's website, six liraglutide injections were approved in China at that time. CDE's register shows further supplementary filings by other domestic makers. The 2025 national insurance list includes liraglutide injection for type 2 diabetes only.
Last verified 2026-09-29 · how we verify
Liraglutide elsewhere
Sources (4)
- 01Tonghua Dongbao: liraglutide injection obtains drug registration certificate (通化东宝关于利拉鲁肽注射液获得药品注册证书的公告)Tonghua Dongbao Pharmaceutical (Shanghai Stock Exchange filing) · 2023-12-05 · accessed 2026-09-29
- 02Zhifei Biological: liraglutide injection obtains drug registration certificate (智飞生物关于利拉鲁肽注射液获得药品注册证书的公告)Chongqing Zhifei Biological Products (Shenzhen Stock Exchange filing) · 2026-07-10 · accessed 2026-09-29
- 03National Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug List (2025 edition), effective 2026-01-01National Healthcare Security Administration (NHSA) · 2025-12 · accessed 2026-09-29
- 04CDE public register of accepted drug applications (受理品种目录浏览)Center for Drug Evaluation (CDE), NMPA · 2026-09-29 · accessed 2026-09-29